A systematic review of microwave ablation for colorectal pulmonary metastases

C. Q. Y. Tan; A. Ho; H. A. Robinson; L. Huang; Praveen Ravindran; Daniel L. Chan; N. Alzahrani; D. L. Morris

doi:10.21873/anticanres.16461

A systematic review of microwave ablation for colorectal pulmonary metastases

C. Q. Y. Tan, A. Ho, H. A. Robinson, L. Huang, Praveen Ravindran, Daniel L. Chan, N. Alzahrani, D. L. Morris

Western Sydney University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background/Aim: Pulmonary metastases are the second most common site of metastasis in colorectal cancer after the liver, and microwave ablation (MWA) for its treatment has grown in popularity in patients who are not suitable for pulmonary metastatectomy. However, its long-term efficacy remains unknown. Materials and Methods: A systematic review was conducted in July 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using PubMed, EMBASE, Scopus, and Cochrane databases. Studies adopting MWA for colorectal cancer pulmonary metastases were included. Results: A total of 488 lesions were ablated in 230 patients across eight studies. The median duration of ablation was 10 minutes. The mean length of stay in hospital was 2.3 days. Complications included pneumothorax in 128 (52%) patients; pneumonia, which occurred in 4 (1.7%) patients, and pulmonary haemorrhage in 23 (10.0%) patients. Complete remission was achieved in 85 (37.0%) patients, local control was achieved in 103 (44.8%) patients, and residual or progressive disease remained in 85 (37.0%). Survival post ablation at 1 year was 89.2% and at 3 years was 40.3%. Post-ablation disease-free survival was 43.2% at 3 years. Conclusion: MWA is an alternative treatment for pulmonary metastases of colorectal cancer. It has competitive theoretical properties and local recurrence rate compared to radiofrequency ablation.

Original language	English
Pages (from-to)	2899-2907
Number of pages	9
Journal	Anticancer Research
Volume	43
Issue number	7
DOIs	https://doi.org/10.21873/anticanres.16461
Publication status	Published - Jul 2023

Bibliographical note

Publisher Copyright:
© 2023 International Institute of Anticancer Research. All rights reserved.

Open Access - Access Right Statement

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.16461

Cite this

@article{1975cb1ad74d44c481046027ffdaed47,

title = "A systematic review of microwave ablation for colorectal pulmonary metastases",

abstract = "Background/Aim: Pulmonary metastases are the second most common site of metastasis in colorectal cancer after the liver, and microwave ablation (MWA) for its treatment has grown in popularity in patients who are not suitable for pulmonary metastatectomy. However, its long-term efficacy remains unknown. Materials and Methods: A systematic review was conducted in July 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using PubMed, EMBASE, Scopus, and Cochrane databases. Studies adopting MWA for colorectal cancer pulmonary metastases were included. Results: A total of 488 lesions were ablated in 230 patients across eight studies. The median duration of ablation was 10 minutes. The mean length of stay in hospital was 2.3 days. Complications included pneumothorax in 128 (52%) patients; pneumonia, which occurred in 4 (1.7%) patients, and pulmonary haemorrhage in 23 (10.0%) patients. Complete remission was achieved in 85 (37.0%) patients, local control was achieved in 103 (44.8%) patients, and residual or progressive disease remained in 85 (37.0%). Survival post ablation at 1 year was 89.2% and at 3 years was 40.3%. Post-ablation disease-free survival was 43.2% at 3 years. Conclusion: MWA is an alternative treatment for pulmonary metastases of colorectal cancer. It has competitive theoretical properties and local recurrence rate compared to radiofrequency ablation.",

author = "Tan, {C. Q. Y.} and A. Ho and Robinson, {H. A.} and L. Huang and Praveen Ravindran and Chan, {Daniel L.} and N. Alzahrani and Morris, {D. L.}",

year = "2023",

month = jul,

doi = "10.21873/anticanres.16461",

language = "English",

volume = "43",

pages = "2899--2907",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

TY - JOUR

T1 - A systematic review of microwave ablation for colorectal pulmonary metastases

AU - Tan, C. Q. Y.

AU - Ho, A.

AU - Robinson, H. A.

AU - Huang, L.

AU - Ravindran, Praveen

AU - Chan, Daniel L.

AU - Alzahrani, N.

AU - Morris, D. L.

PY - 2023/7

Y1 - 2023/7

N2 - Background/Aim: Pulmonary metastases are the second most common site of metastasis in colorectal cancer after the liver, and microwave ablation (MWA) for its treatment has grown in popularity in patients who are not suitable for pulmonary metastatectomy. However, its long-term efficacy remains unknown. Materials and Methods: A systematic review was conducted in July 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using PubMed, EMBASE, Scopus, and Cochrane databases. Studies adopting MWA for colorectal cancer pulmonary metastases were included. Results: A total of 488 lesions were ablated in 230 patients across eight studies. The median duration of ablation was 10 minutes. The mean length of stay in hospital was 2.3 days. Complications included pneumothorax in 128 (52%) patients; pneumonia, which occurred in 4 (1.7%) patients, and pulmonary haemorrhage in 23 (10.0%) patients. Complete remission was achieved in 85 (37.0%) patients, local control was achieved in 103 (44.8%) patients, and residual or progressive disease remained in 85 (37.0%). Survival post ablation at 1 year was 89.2% and at 3 years was 40.3%. Post-ablation disease-free survival was 43.2% at 3 years. Conclusion: MWA is an alternative treatment for pulmonary metastases of colorectal cancer. It has competitive theoretical properties and local recurrence rate compared to radiofrequency ablation.

AB - Background/Aim: Pulmonary metastases are the second most common site of metastasis in colorectal cancer after the liver, and microwave ablation (MWA) for its treatment has grown in popularity in patients who are not suitable for pulmonary metastatectomy. However, its long-term efficacy remains unknown. Materials and Methods: A systematic review was conducted in July 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using PubMed, EMBASE, Scopus, and Cochrane databases. Studies adopting MWA for colorectal cancer pulmonary metastases were included. Results: A total of 488 lesions were ablated in 230 patients across eight studies. The median duration of ablation was 10 minutes. The mean length of stay in hospital was 2.3 days. Complications included pneumothorax in 128 (52%) patients; pneumonia, which occurred in 4 (1.7%) patients, and pulmonary haemorrhage in 23 (10.0%) patients. Complete remission was achieved in 85 (37.0%) patients, local control was achieved in 103 (44.8%) patients, and residual or progressive disease remained in 85 (37.0%). Survival post ablation at 1 year was 89.2% and at 3 years was 40.3%. Post-ablation disease-free survival was 43.2% at 3 years. Conclusion: MWA is an alternative treatment for pulmonary metastases of colorectal cancer. It has competitive theoretical properties and local recurrence rate compared to radiofrequency ablation.

UR - https://hdl.handle.net/1959.7/uws:76957

U2 - 10.21873/anticanres.16461

DO - 10.21873/anticanres.16461

M3 - Article

SN - 0250-7005

VL - 43

SP - 2899

EP - 2907

JO - Anticancer Research

JF - Anticancer Research

IS - 7

ER -

A systematic review of microwave ablation for colorectal pulmonary metastases

Abstract

Bibliographical note

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this